Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a global Phase 2b trial in people with obesity or overweight with weight-related comorbidities comparing once-weekly subcutaneously administered petrelintide, a long-acting amylin analog, versus placebo with regards to effects on body weight, safety, and tolerability.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma upgraded to Buy from Hold at SEB Equities
- Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact
- William Blair upgrades Zealand to Outperform on recent selloff
- Zealand Pharma upgraded to Outperform from Market Perform at William Blair
- Zealand Pharma removed from European Conviction List at Goldman Sachs